View Item 

Show simple item record

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations
dc.contributor.authorYatham, Lakshmi N.
dc.contributor.authorChakrabarty, Trisha
dc.contributor.authorBond, David J.
dc.contributor.authorSchaffer, Ayal
dc.contributor.authorBeaulieu, Serge
dc.contributor.authorParikh, Sagar V.
dc.contributor.authorMcIntyre, Roger S.
dc.contributor.authorMilev, Roumen V.
dc.contributor.authorAlda, Martin
dc.contributor.authorVazquez, Gustavo
dc.contributor.authorRavindran, Arun V.
dc.contributor.authorFrey, Benicio N.
dc.contributor.authorSharma, Verinder
dc.contributor.authorGoldstein, Benjamin I.
dc.contributor.authorRej, Soham
dc.contributor.authorO’Donovan, Claire
dc.contributor.authorTourjman, Valerie
dc.contributor.authorKozicky, Jan-Marie
dc.contributor.authorKauer-Sant’Anna, Marcia
dc.contributor.authorMalhi, Gin
dc.contributor.authorSuppes, Trisha
dc.contributor.authorVieta, Eduard
dc.contributor.authorKapczinski, Flavio
dc.contributor.authorKanba, Shigenobu
dc.contributor.authorLam, Raymond W.
dc.contributor.authorKennedy, Sidney H.
dc.contributor.authorCalabrese, Joseph
dc.contributor.authorBerk, Michael
dc.contributor.authorPost, Robert
dc.date.accessioned2022-01-06T15:47:59Z
dc.date.available2023-01-06 10:47:58en
dc.date.available2022-01-06T15:47:59Z
dc.date.issued2021-12
dc.identifier.citationYatham, Lakshmi N.; Chakrabarty, Trisha; Bond, David J.; Schaffer, Ayal; Beaulieu, Serge; Parikh, Sagar V.; McIntyre, Roger S.; Milev, Roumen V.; Alda, Martin; Vazquez, Gustavo; Ravindran, Arun V.; Frey, Benicio N.; Sharma, Verinder; Goldstein, Benjamin I.; Rej, Soham; O’Donovan, Claire ; Tourjman, Valerie; Kozicky, Jan-Marie ; Kauer‐Sant’Anna, Marcia ; Malhi, Gin; Suppes, Trisha; Vieta, Eduard; Kapczinski, Flavio; Kanba, Shigenobu; Lam, Raymond W.; Kennedy, Sidney H.; Calabrese, Joseph; Berk, Michael; Post, Robert (2021). "Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations." Bipolar Disorders (8): 767-788.
dc.identifier.issn1398-5647
dc.identifier.issn1399-5618
dc.identifier.urihttps://hdl.handle.net/2027.42/171126
dc.description.abstractObjectivesThe 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided clinicians with pragmatic treatment recommendations for bipolar disorder (BD). While these guidelines included commentary on how mixed features may direct treatment selection, specific recommendations were not provided- a critical gap which the current update aims to address.MethodOverview of research regarding mixed presentations in BD, with treatment recommendations developed using a modified CANMAT/ISBD rating methodology. Limitations are discussed, including the dearth of high- quality data and reliance on expert opinion.ResultsNo agents met threshold for first- line treatment of DSM- 5 manic or depressive episodes with mixed features. For mania + mixed features second- line treatment options include asenapine, cariprazine, divalproex, and aripiprazole. In depression + mixed features, cariprazine and lurasidone are recommended as second- line options. For DSM- IV defined mixed episodes, with a longer history of research, asenapine and aripiprazole are first- line, and olanzapine (monotherapy or combination), carbamazepine, and divalproex are second- line. Research on maintenance treatments following a DSM- 5 mixed presentation is extremely limited, with third- line recommendations based on expert opinion. For maintenance treatment following a DSM- IV mixed episode, quetiapine (monotherapy or combination) is first- line, and lithium and olanzapine identified as second- line options.ConclusionThe CANMAT and ISBD groups hope these guidelines provide valuable support for clinicians providing care to patients experiencing mixed presentations, as well as further influence investment in research to improve diagnosis and treatment of this common and complex clinical state.
dc.publisherAmerican Psychiatric Association
dc.publisherWiley Periodicals, Inc.
dc.subject.otherpharmacotherapy
dc.subject.othermixed features
dc.subject.otherguidelines
dc.subject.otherbipolar disorder
dc.titleCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPsychology
dc.subject.hlbtoplevelSocial Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171126/1/bdi13135.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171126/2/bdi13135_am.pdf
dc.identifier.doi10.1111/bdi.13135
dc.identifier.sourceBipolar Disorders
dc.identifier.citedreferenceCiapparelli A, Dell’Osso L, Tundo A, et al. Electroconvulsive therapy in medication- nonresponsive patients with mixed mania and bipolar depression. J Clin Psychiatry. 2001; 62: 552 - 555.
dc.identifier.citedreferenceMedda P, Toni C, Mariani MG, De Simone L, Mauri M, Perugi G. Electroconvulsive therapy in 197 patients with a severe, drug- resistant bipolar mixed state: treatment outcome and predictors of response. J Clin Psychiatry. 2015; 76: 1168 - 1173.
dc.identifier.citedreferencePalma M, Ferreira B, Borja- Santos N, Trancas B, Monteiro C, Cardoso G. Efficacy of electroconvulsive therapy in bipolar disorder with mixed features. Depress Res Treat. 2016; 2016: 8306071.
dc.identifier.citedreferenceCutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended- release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double- blind, 3- week trial. Clin Ther. 2011; 33: 1643 - 1658.
dc.identifier.citedreferenceMiguel SRPS, Lima AFBS, Cruz LN, et al. Bipolar disorder mixed episodes: a pragmatic trial of a public health treatment effectiveness. Value Health Reg Issues. 2018; 17: 158 - 163.
dc.identifier.citedreferenceVieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active- controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar i disorder. Bipolar Disord. 2010; 12: 230 - 243.
dc.identifier.citedreferenceBerwaerts J, Xu H, Nuamah I, Lim P, Hough D. Evaluation of the efficacy and safety of paliperidone extended- release in the treatment of acute mania:a randomized, double- blind, dose- response study. J Affect Disord. 2012; 136: e51 - e60.
dc.identifier.citedreferencePerlis RH, Baker RW, Zarate CA, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double- blind trial. J Clin Psychiatry. 2006; 67: 1747 - 1753.
dc.identifier.citedreferenceSachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double- blind, placebo- controlled comparison of efficacy and safety. Am J Psychiatry. 2002; 159: 1146 - 1154.
dc.identifier.citedreferenceSingh V, Bowden CL, Mintz J. Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. Int Clin Psychopharmacol. 2013; 28: 91 - 95.
dc.identifier.citedreferenceWoo YS, Bahk W- M, Jon D- I, et al. Risperidone in the treatment of mixed state bipolar patients: results from a 24- week, multicenter, open- label study in Korea. Psychiatry Clin Neurosci. 2010; 64: 28 - 37.
dc.identifier.citedreferencePallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: an exploratory study. J Affect Disord. 2014; 157: 66 - 71.
dc.identifier.citedreferenceDauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo- controlled adjunctive trial. Psychopharmacol Bull. 2011; 44: 5 - 17.
dc.identifier.citedreferenceKushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double- blind placebo- controlled trials. Bipolar Disord. 2006; 8: 15 - 27.
dc.identifier.citedreferenceVieta E, Suppes T, Ekholm B, Udd M, Gustafsson U. Long- term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord. 2012; 142: 36 - 44.
dc.identifier.citedreferenceCipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta- analysis. BMJ. 2013; 346: f3646.
dc.identifier.citedreferenceTohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double- blind, placebo- controlled study of bipolar I disorder. J Affect Disord. 2009; 116: 43 - 50.
dc.identifier.citedreferenceTohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo- controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163: 247 - 256.
dc.identifier.citedreferenceYatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. 2013; 147: 365 - 372.
dc.identifier.citedreferenceBirmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006; 63: 175 - 183.
dc.identifier.citedreferenceShim IH, Woo YS, Bahk WM. Prevalence rates and clinical implications of bipolar disorder - with mixed features- as defined by DSM- 5. J Affect Disord. 2015; 173: 120 - 125.
dc.identifier.citedreferenceErnst CL, Goldberg JF. Clinical features related to age at onset in bipolar disorder. J Affect Disord. 2004; 82: 21 - 27.
dc.identifier.citedreferenceFindling RL, Earley W, Suppes T, et al. Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. Neuropsychiatr Dis Treat. 2018; 14: 1941 - 1952.
dc.identifier.citedreferenceFindling RL, Landbloom RL, Mackle M, et al. Long- term safety of asenapine in pediatric patients diagnosed with bipolar I disorder: a 50- week open- label, flexible- dose trial. Paediatr Drugs. 2016; 18: 367 - 378.
dc.identifier.citedreferenceFindling RL, Landbloom RL, Szegedi A, et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry. 2015; 54: 1032 - 1041.
dc.identifier.citedreferenceGeller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012; 69: 515 - 528.
dc.identifier.citedreferenceHaas M, DelBello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double- blind, placebo- controlled study. Bipolar Disord. 2009; 11: 687 - 700.
dc.identifier.citedreferenceXiao LE, Ganocy SJ, Findling RL, et al. Baseline characteristics and early response at week 1 predict treatment outcome in adolescents with bipolar manic or mixed episode treated with olanzapine: results from a 3- week, randomized, placebo- controlled trial. J Clin Psychiatry. 2017; 78: e1158 - e2116.
dc.identifier.citedreferenceTohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007; 164: 1547 - 1556.
dc.identifier.citedreferenceFindling RL, Ã avuÅ I, Pappadopulos E, et al. Efficacy, long- term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2013; 23: 545 - 557.
dc.identifier.citedreferenceSingh MK, Pikalov A, Siu C, Tocco M, Loebel A. Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo- controlled trial. J Child Adolesc Psychopharmacol. 2020; 30: 590 - 598.
dc.identifier.citedreferenceDelbello MP, Kowatch RA, Adler CM, et al. A double- blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006; 45: 305 - 313.
dc.identifier.citedreferencePavuluri MN, Henry DB, Carbray JA, Naylor MW, Janicak PG. Divalproex sodium for pediatric mixed mania: a 6- month prospective trial. Bipolar Disord. 2005; 7: 266 - 273.
dc.identifier.citedreferenceFindling RL, Ginsberg LD. The safety and effectiveness of open- label extended- release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat. 2014; 1589- 97.
dc.identifier.citedreferenceFindling RL, McNamara NK, Pavuluri M, et al. Lithium for the maintenance treatment of bipolar I disorder: a double- blind, placebo- controlled discontinuation study. J Am Acad Child Adolesc Psychiatry. 2019; 58: 287 - 96.e4.
dc.identifier.citedreferenceFindling RL, Chang K, Robb A, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo- controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry. 2015; 54: 1020 - 31.e3.
dc.identifier.citedreferenceYoung RC, Mulsant BH, Sajatovic M, et al. GERI- BD: A randomized double- blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017; 174: 1086 - 1093.
dc.identifier.citedreferenceSajatovic M, Coconcea N, Ignacio RV, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12- week, open- label trial. J Clin Psychiatry. 2008; 69: 41 - 46.
dc.identifier.citedreferenceSajatovic M, Dines P, Fuentes- Casiano E, et al. Asenapine in the treatment of older adults with bipolar disorder. Int J Geriatr Psychiatry. 2015; 30: 710 - 719.
dc.identifier.citedreferenceViguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007; 164: 1817 - 1824.
dc.identifier.citedreferenceà elik SB, Bucaktepe GE, UludaÄ A, Bulut Ä°U, Erdem à , AltınbaÅ K. Screening mixed depression and bipolarity in the postpartum period at a primary health care center. Compr Psychiatry. 2016; 71: 57 - 62.
dc.identifier.citedreferenceAltinbas K. Unipolar versus bipolar mixed depression: interpretations for the clinical practice. Bipolar Disord. 2014; 16: 53.
dc.identifier.citedreferenceViguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry. 2011; 168: 1179 - 1185.
dc.identifier.citedreferenceGanjekar S, Desai G, Chandra PS. A comparative study of psychopathology, symptom severity, and short- term outcome of postpartum and nonpostpartum mania. Bipolar Disord. 2013; 15: 713 - 718.
dc.identifier.citedreferenceBlackmore ER, Rubinow DR, O’Connor TG, et al. Reproductive outcomes and risk of subsequent illness in women diagnosed with postpartum psychosis. Bipolar Disord. 2013; 15: 394 - 404.
dc.identifier.citedreferenceSharma V, Doobay M, Baczynski C. Bipolar postpartum depression: an update and recommendations. J Affect Disord. 2017; 219: 105 - 111.
dc.identifier.citedreferenceSharma V, Khan M, Sommerdyk C. Quetiapine in the acute treatment of bipolar postpartum depression: a chart review. J Clin Psychopharmacol. 2015; 35: 733 - 735.
dc.identifier.citedreferenceSharma V. Are mixed symptoms a red flag for conversion of postpartum depression to bipolar disorder? Prim Care Companion CNS Disord. 2018; 20: 17l02201.
dc.identifier.citedreferenceVerdolini N, Hidalgo- Mazzei D, Murru A, et al. Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatr Scand. 2018; 138: 196 - 222.
dc.identifier.citedreferenceAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.. 5 th ed. American Psychiatric Publishing; 2013.
dc.identifier.citedreferenceKusumakar V, Yatham LN. The treatment of bipolar disorder: review of the literature, guidelines and options: introduction. Can J Psychiatry. 1997; 42: 67S - 100S.
dc.identifier.citedreferenceYatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005; 7 ( Suppl 3 ): 5 - 69.
dc.identifier.citedreferenceYatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11: 225 - 255.
dc.identifier.citedreferenceYatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15: 1 - 44.
dc.identifier.citedreferenceYatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20: 97 - 170.
dc.identifier.citedreferenceVieta E, Valenti M. Mixed states in DSM- 5: implications for clinical care, education, and research. J Affect Disord. 2013; 148: 28 - 36.
dc.identifier.citedreferenceVázquez GH, Lolich M, Cabrera C, et al. Mixed symptoms in major depressive and bipolar disorders: a systematic review. J Affect Disord. 2018; 225: 756 - 760.
dc.identifier.citedreferenceGoldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP- BD. Am J Psychiatry. 2009; 166: 173 - 181.
dc.identifier.citedreferenceGonzález- Pinto A, Barbeito S, Alonso M, et al. Poor long- term prognosis in mixed bipolar patients: 10- year outcomes in the Vitoria prospective naturalistic study in Spain. J Clin Psychiatry. 2011; 72: 671 - 676.
dc.identifier.citedreferenceMcIntyre RS, Soczynska JK, Cha DS, et al. The prevalence and illness characteristics of DSM- 5- defined - mixed feature specifier- in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2015; 172: 259 - 264.
dc.identifier.citedreferenceMcIntyre RS, Ng- Mak D, Chuang C- C, et al. Major depressive disorder with subthreshold hypomanic (mixed) features: a real- world assessment of treatment patterns and economic burden. J Affect Disord. 2017; 210: 332 - 337.
dc.identifier.citedreferencePerugi G, Angst J, Azorin J- M, et al. Mixed features in patients with a major depressive episode: the BRIDGE- II- MIX study. J Clin Psychiatry. 2015; 76: e351 - e358.
dc.identifier.citedreferenceSwann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an International Society for Bipolar Disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170: 31 - 42.
dc.identifier.citedreferenceGoldberg JF, McElroy SL. Bipolar mixed episodes: characteristics and comorbidities. J Clin Psychiatry. 2007; 68: e25.
dc.identifier.citedreferenceSeo HJ, Wang HR, Jun TY, Woo YS, Bahk WM. Factors related to suicidal behavior in patients with bipolar disorder: the effect of mixed features on suicidality. Gen Hosp Psychiatry. 2016; 39: 91 - 96.
dc.identifier.citedreferencePacchiarotti I, Mazzarini L, Kotzalidis GD, et al. Mania and depression: mixed, not stirred. Eur Neuropsychopharmacol. 2011; 21: S419.
dc.identifier.citedreferenceFiedorowicz JG, Persons JE, Assari S, et al. Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. J Affect Disord. 2019; 246: 775 - 782.
dc.identifier.citedreferenceMiller S, Suppes T, Mintz J, et al. Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow- up in the Stanley Bipolar Network. Am J Psychiatry. 2016; 173: 1015 - 1023.
dc.identifier.citedreferenceStahl SM, Morrissette DA, Faedda G, et al. Guidelines for the recognition and management of mixed depression. CNS Spectr. 2017; 22: 203 - 219.
dc.identifier.citedreferenceGrunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long- term treatment of mixed states in bipolar disorder. World J Biol Psychiatr. 2018; 19: 2 - 58.
dc.identifier.citedreferenceMalhi GS, Bell E, Boyce P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Bipolar Disord. 2020; 22: 805- .
dc.identifier.citedreferenceAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 th ed., text rev. American Psychiatric Association; 2000.
dc.identifier.citedreferenceSani G, Vöhringer PA, Napoletano F, et al. Koukopoulos׳ diagnostic criteria for mixed depression: a validation study. J Affect Disord. 2014; 164: 14 - 18.
dc.identifier.citedreferenceVieta E, Grunze H, Azorin JM, Fagiolini A. Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM- 5: results from the impact self- reported online survey. J Affect Disord. 2014; 156: 206 - 213.
dc.identifier.citedreferenceSalvatore P, Baldessarini RJ, Centorrino F, et al. Weygandt’s on the mixed states of manic- depressive insanity: a translation and commentary on its significance in the evolution of the concept of bipolar disorder. Harv Rev Psychiatry. 2002; 10: 255 - 275.
dc.identifier.citedreferenceMalhi GS, Irwin L, Hamilton A, et al. Modelling mood disorders: an ACE solution? Bipolar Disord. 2018; 20: 4 - 16.
dc.identifier.citedreferenceKoukopoulos A, Sani G. DSM- 5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand. 2014; 129: 4 - 16.
dc.identifier.citedreferenceSuppes T, Mintz J, McElroy SL, et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex- specific phenomenon. Arch Gen Psychiatry. 2005; 62: 1089 - 1096.
dc.identifier.citedreferenceAngst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry. 2011; 68: 791 - 798.
dc.identifier.citedreferenceMcElroy SL, Keck PE. Dysphoric mania, mixed states, and mania with mixed features specifier: are we mixing things up? CNS Spectr. 2017; 22: 170 - 176.
dc.identifier.citedreferenceMalhi GS, Fritz K, Allwang C, et al. Are manic symptoms that - dip- into depression the essence of mixed features? J Affect Disord. 2016; 192: 104 - 108.
dc.identifier.citedreferenceSuppes T, Eberhard J, Lemming O, Young AH, McIntyre RS. Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. Int J Bipolar Disord. 2017; 5: 36.
dc.identifier.citedreferenceMalhi GS, Fritz K, Elangovan P, Irwin L. Mixed states: modelling and management. CNS Drugs. 2019; 33: 301 - 313.
dc.identifier.citedreferencePerugi G, Angst J, Azorin J- M, et al. Relationships between mixed features and borderline personality disorder in 2811 patients with major depressive episode. Acta Psychiatr Scand. 2016; 133: 133 - 143.
dc.identifier.citedreferenceShim IH, Lee J, Kim M- D, et al. The prevalence and diagnostic classification of mixed features in patients with major depressive episodes: a multicenter study based on the DSM- 5. Int J Methods Psychiatr Res. 2019; 28: e1773.
dc.identifier.citedreferenceShalini Theodore R, Ramirez Basco M, Biggan JR. Diagnostic disagreements in bipolar disorder: the role of substance abuse comorbidities. Depress Res Treat. 2012; 2012: 435486.
dc.identifier.citedreferenceSasson Y, Chopra M, Harrari E, Amitai K, Zohar J. Bipolar comorbidity: from diagnostic dilemmas to therapeutic challenge. Int J Neuropsychopharmacol. 2003; 6: 139 - 144.
dc.identifier.citedreferenceMontgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382 - 389.
dc.identifier.citedreferenceYoung RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133: 429 - 435.
dc.identifier.citedreferenceZimmerman M, Chelminski I, Young D, Dalrymple K, Martinez JH. A clinically useful self- report measure of the DSM- 5 mixed features specifier of major depressive disorder. J Affect Disord. 2014; 168: 357 - 362.
dc.identifier.citedreferenceBeidas RS, Stewart RE, Walsh L, et al. Free, brief, and validated: standardized instruments for low- resource mental health settings. Cogn Behav Pract. 2015; 22: 5 - 19.
dc.identifier.citedreferenceSachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. Bipolar Disord. 2002; 4: 323 - 327.
dc.identifier.citedreferenceRichter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology. 1998; 31: 160 - 168.
dc.identifier.citedreferenceMitchell AJ, Yadegarfar M, Gill J, Stubbs B. Case finding and screening clinical utility of the patient health questionnaire (PHQ- 9 and PHQ- 2) for depression in primary care: a diagnostic meta- analysis of 40 studies. BJPsych Open. 2016; 2: 127 - 138.
dc.identifier.citedreferenceRush AJohn, Trivedi MH, Ibrahim HM, et al. The 16- item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS- C), and self- report (QIDS- SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003; 54: 573 - 583.
dc.identifier.citedreferenceAltman EG, Hedeker D, Peterson JL, Davis JM. The Altman Self- Rating Mania Scale. Biol Psychiatry. 1997; 42: 948 - 955.
dc.identifier.citedreferenceBerk M, Malhi GS, Cahill C, et al. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord. 2007; 9: 571 - 579.
dc.identifier.citedreferenceSani G, Vöhringer PA, Barroilhet SA, Koukopoulos AE, Ghaemi SN. The Koukopoulos Mixed Depression Rating Scale (KMDRS): an International Mood Network (IMN) validation study of a new mixed mood rating scale. J Affect Disord. 2018; 232: 9 - 16.
dc.identifier.citedreferencePacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170: 1249 - 1262.
dc.identifier.citedreferenceSani G, Napoletano F, Vöhringer PA, et al. Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom. 2014; 83: 213 - 221.
dc.identifier.citedreferenceFrye MA, Helleman G, McElroy SL, et al. Correlates of treatment- emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009; 166: 164 - 172.
dc.identifier.citedreferenceO’Donovan C, Garnham JS, Hajek T, Alda M. Antidepressant monotherapy in pre- bipolar depression; predictive value and inherent risk. J Affect Disord. 2008; 107: 293 - 298.
dc.identifier.citedreferenceBond DJ, Noronha MM, Kauer- Sant’Anna M, Lam RW, Yatham LN. Antidepressant- associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta- analysis. J Clin Psychiatry. 2008; 69: 1589 - 1601.
dc.identifier.citedreferenceAltshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second- generation antidepressants. Focus (Am Psychiatr Publ). 2019; 17: 322 - 324.
dc.identifier.citedreferenceStahl SM. Stahl- s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4 th ed. Cambridge University Press; 2013.
dc.identifier.citedreferenceSalem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic- induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017; 15: 789 - 798.
dc.identifier.citedreferenceGardner DM, Murphy AL, Kutcher S, et al. Evidence review and clinical guidance for the use of ziprasidone in Canada. Ann of Gen Psych. 2013; 12: 1.
dc.identifier.citedreferenceSchaffer A, Isometsä ET, Azorin J- M, et al. A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: part II of a report of the International Society for Bipolar Disorders task force on suicide in bipolar disorder. Aust N Z J Psychiatry. 2015; 49: 1006 - 1020.
dc.identifier.citedreferenceYoung AH, Eberhard J. Evaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder. Neuropsychiatr Dis Treat. 2015; 11: 1137 - 1143.
dc.identifier.citedreferenceHolma KM, Haukka J, Suominen K, et al. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder. Bipolar Disord. 2014; 16: 652 - 661.
dc.identifier.citedreferencePersons JE, Coryell WH, Solomon DA, Keller MB, Endicott J, Fiedorowicz JG. Mixed state and suicide: is the effect of mixed state on suicidal behavior more than the sum of its parts? Bipolar Disord. 2018; 20: 35 - 41.
dc.identifier.citedreferenceLage RR, Santana CMT, Nardi AE, Cheniaux E. Mixed states and suicidal behavior: a systematic review. Trends Psychiatry Psychother. 2019; 41: 191 - 200.
dc.identifier.citedreferenceSchaffer A, Van Meter A, Sinyor M. The best defense is a good offense: proactive approaches for suicide prevention in bipolar disorder. Bipolar Disord. 2020; 22: 191 - 192.
dc.identifier.citedreferenceSchaffer A, Isometsä ET, Tondo L, et al. Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: part I of a report of the International Society for Bipolar Disorders task force on suicide in bipolar disorder. Aust N Z J Psychiatry. 2015; 49: 785 - 802.
dc.identifier.citedreferenceO’Brien B, Lee D, Swann AC, Mathew SJ, Lijffijt M. Psychotherapy for mixed depression and mixed mania. Psychiatr Clin North Am. 2020; 43: 199 - 211.
dc.identifier.citedreferenceCassidy F, Ahearn E, Carroll BJ. Concordance of self- rated and observer- rated dysphoric symptoms in mania. J Affect Disord. 2009; 114: 294 - 298.
dc.identifier.citedreferenceAngst J. Bipolar disorders in DSM- 5: strengths, problems and perspectives. Int J Bipolar Disord. 2013; 1: 12.
dc.identifier.citedreferenceMcIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM- 5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013; 150: 378 - 383.
dc.identifier.citedreferenceBerk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate- to- severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015; 76: 728 - 734.
dc.identifier.citedreferenceMcIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord. 2019; 257: 600 - 606.
dc.identifier.citedreferenceSwann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997; 54: 37 - 42.
dc.identifier.citedreferenceSuppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008; 107: 145 - 154.
dc.identifier.citedreferenceThase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo- controlled studies. J Clin Psychopharmacol. 2008; 28: 13 - 20.
dc.identifier.citedreferenceFountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta- analysis. J Affect Disord. 2011; 133: 361 - 370.
dc.identifier.citedreferenceSachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3- week placebo- controlled study. Journal of Psychopharmacology. 2006; 20: 536 - 546.
dc.identifier.citedreferenceStahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double- blind studies. J Affect Disord. 2010; 122: 39 - 45.
dc.identifier.citedreferenceTohen M, McIntyre RS, Kanba S, Fujikoshi S, Katagiri H. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM- 5. J Affect Disord. 2014; 168: 136 - 141.
dc.identifier.citedreferenceGonzalez- Pinto A, Lalaguna B, Mosquera F, et al. Use of olanzapine in dysphoric mania. J Affect Disord. 2001; 66: 247 - 253.
dc.identifier.citedreferenceGonzalez- Pinto A, Tohen M, Lalaguna B, et al. Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol. 2002; 22: 450 - 454.
dc.identifier.citedreferenceSuppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150: 37 - 43.
dc.identifier.citedreferenceWeisler RH, Hirschfeld R, Cutler AJ, et al. Extended- release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double- blind, placebo- controlled trials. CNS Drugs. 2006; 20: 219 - 231.
dc.identifier.citedreferenceKatagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double- blind, placebo- and haloperidol- controlled study. J Affect Disord. 2012; 136: 476 - 484.
dc.identifier.citedreferenceBetzler F, Stover LA, Sterzer P, Kohler S. Mixed states in bipolar disorder- changes in DSM- 5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21: 244 - 258.
dc.identifier.citedreferenceKoukopoulos A, Sani G, Ghaemi SN. Mixed features of depression: why DSM- 5 is wrong (and so was DSM- IV). Br J Psychiatry. 2013; 203: 3 - 5.
dc.identifier.citedreferenceParker G. The DSM- 5 classification of mood disorders: some fallacies and fault lines. Acta Psychiatr Scand. 2014; 129: 404 - 409.
dc.identifier.citedreferenceMcIntyre RS, Suppes T, Earley W, Patel M, Stahl SM. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo- controlled studies. CNS Spectr. 2019; 1- 9.
dc.identifier.citedreferenceMcIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo- controlled trial. J Clin Psychiatry. 2015; 76: 398 - 405.
dc.identifier.citedreferenceTohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014; 164: 57 - 62.
dc.identifier.citedreferenceBenazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009; 70: 1424 - 1431.
dc.identifier.citedreferenceSuttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta- analysis. Drug Des Devel Ther. 2014; 8: 827 - 838.
dc.identifier.citedreferenceKishi T, Ikuta T, Sakuma K, Matsuda Y, Iwata N. Comparison of quetiapine immediate- and extended- release formulations for bipolar depression: a systematic review and network meta- analysis of double- blind, randomized placebo- controlled trials. J Psychiatr Res. 2019; 115: 121 - 128.
dc.identifier.citedreferenceScherk H, Pajonk FG, Leucht S. Second- generation antipsychotic agents in the treatment of acute mania: a systematic review and meta- analysis of randomized controlled trials. Arch Gen Psychiatry. 2007; 64: 442 - 455.
dc.identifier.citedreferenceWeisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry. 2011; 72: 1452 - 1464.
dc.identifier.citedreferencePatkar A, Gilmer W, Pae C- U, et al. A 6 week randomized double- blind placebo- controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7: e34757.
dc.identifier.citedreferenceSchoeyen HK, Kessler U, Andreassen OA, et al. Treatment- resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm- based pharmacological treatment. Am J Psychiatry. 2015; 172: 41 - 51.
dc.identifier.citedreferenceCassidy F, Yatham LN, Berk M, Grof P. Pure and mixed manic subtypes: a review of diagnostic classification and validation. Bipolar Disord. 2008; 10: 131 - 143.
dc.identifier.citedreferenceCassidy F, Carroll BJ. The clinical epidemiology of pure and mixed manic episodes. Bipolar Disord. 2001; 3: 35 - 40.
dc.identifier.citedreferenceVieta E, Morralla C. Prevalence of mixed mania using 3 definitions. J Affect Disord. 2010; 125: 61 - 73.
dc.identifier.citedreferenceCassidy F, Murry E, Forest K, Carroll BJ. Signs and symptoms of mania in pure and mixed episodes. J Affect Disord. 1998; 50: 187 - 201.
dc.identifier.citedreferenceSingh V, Bowden CL, Gonzalez JM, et al. Discriminating primary clinical states in bipolar disorder with a comprehensive symptom scale. Acta Psychiatr Scand. 2013; 127: 145 - 152.
dc.identifier.citedreferenceGonzález- Pinto A, Aldama A, González Pinto A, et al. Dimensions of mania: differences between mixed and pure episodes. Eur Psychiatry. 2004; 19: 307 - 310.
dc.identifier.citedreferenceAkiskal HS, Hantouche EG, Bourgeois ML, et al. Gender, temperament, and the clinical picture in dysphoric mixed mania: findings from a French national study (EPIMAN). J Affect Disord. 1998; 50: 175 - 186.
dc.identifier.citedreferenceAzorin J, Sapin C, Weiller E, Hansen K. Effects of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post- hoc analyses. Int Clin Psychopharmacol. 2012; 28: e49 - e50.
dc.identifier.citedreferenceMcIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3- week, randomized, placebo- controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11: 673 - 686.
dc.identifier.citedreferenceBaldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania treatment responses in subgroups. J Clin Psychopharmacol. 2003; 23: 370 - 376.
dc.identifier.citedreferenceHouston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine- divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double- blind, placebo- controlled study. J Clin Psychiatry. 2009; 70: 1540 - 1547.
dc.identifier.citedreferenceTohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59: 62 - 69.
dc.identifier.citedreferenceWeisler RH, Kalali AH, Ketter TA, et al. A multicenter, randomized, double- blind, placebo- controlled trial of extended- release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65: 478 - 484.
dc.identifier.citedreferenceBowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo- controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006; 67: 1501 - 1510.
dc.identifier.citedreferenceKeck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three- week, placebo- controlled, double- blind, randomized trial. Am J Psychiatry. 2003; 160: 741 - 748.
dc.identifier.citedreferenceTohen M, Castillo J, Pope HG Jr, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol. 1994; 14: 67 - 70.
dc.identifier.citedreferenceValenti M, Benabarre A, Garcia- Amador M, Molina O, Bernardo M, Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. Eur Psychiatry. 2008; 23: 53 - 56.
dc.identifier.citedreferenceMedda P, Perugi G, Zanello S, Ciuffa M, Rizzato S, Cassano GB. Comparative response to electroconvulsive therapy in medication- resistant bipolar I patients with depression and mixed state. Journal of ECT. 2010; 26: 82 - 86.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bdi13135.pdf
Size:
2.951MB
Format:
PDF
View/Open
Name:
bdi13135_am.pdf
Size:
590.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.